Kolumne, ORE

Original-Research: Vectron Systems AG - from GBC AG Classification of GBC AG to Vectron Systems AG Company Name: Vectron Systems AG ISIN: DE000A0KEXC7 Reason for the research: Research Comment Recommendation: BUY Target price: 10.00 EUR Target price on sight of: 31.12.2024 Last rating change: Analyst: Cosmin Filker, Matthias Greiffenberger Preliminary figures for 2023: Sales and earnings development in line with expectations, rating: BUY Vectron Systems AG (Vectron for short) published its preliminary figures for the past fiscal year 2023 on 21 February 2024.

26.02.2024 - 11:31:33

Original-Research: Vectron Systems AG (von GBC AG): BUY


Original-Research: Vectron Systems AG - from GBC AG

Classification of GBC AG to Vectron Systems AG

Company Name: Vectron Systems AG
ISIN: DE000A0KEXC7

Reason for the research: Research Comment
Recommendation: BUY
Target price: 10.00 EUR
Target price on sight of: 31.12.2024
Last rating change: 
Analyst: Cosmin Filker, Matthias Greiffenberger

Preliminary figures for 2023: Sales and earnings development in line with
expectations, rating: BUY
 
Vectron Systems AG (Vectron for short) published its preliminary figures
for the past fiscal year 2023 on 21 February 2024. With sales revenue of EUR
37.4 million (previous year: EUR 25.2 million), the company not only
significantly exceeded the previous year's figure by 48%, but also returned
to its growth path as expected. This figure was in the upper half of the
sales guidance, which forecast sales in a range of EUR 36.0 million to EUR 37.8
million. Our forecast (GBC estimate: EUR 38.6 million) was also almost
achieved.
 
According to our calculations, Vectron sales increased by 11% to EUR 28.0
million (previous year: EUR 25.2 million). The main reason for the sales
growth in the Vectron division (POS systems and digital services) was the
further increase in recurring income by 53% to EUR 13.2 million (previous
year: EUR 8.6 million), which now accounts for 47% (previous year: 34%) of
total sales in this division. This clearly reflects the company's focus on
expanding its digital business in particular. Accordingly, Vectron has
outsourced hardware production to external partners. The sales of acardo
group AG (acardo), which was acquired on 1 January 2023, also contributed
to the overall increase in sales. According to our findings, the inorganic
contribution to sales is likely to have exceeded EUR10 million.
 
Thanks to the expansion of the digital business and the earnings
contribution of the acquired acardo, the turnaround was achieved with
EBITDA of EUR 3.0 million (previous year: EUR -3.9 million). At the same time,
the preliminary EBITDA was at the upper end of the guidance raised in
October, which had forecast EBITDA in a range of EUR 2.2 million to EUR 3.2
million. Our EBITDA estimate (GBC forecast: EUR 3.2 million) was also almost
achieved. EBITDA should be characterised by extraordinary income from the
reversal of provisions.
 
Even if this is a one-off effect, a disproportionately high improvement in
earnings should still be achieved in the current financial year 2024. On
the one hand, the expansion of the digital business will be accompanied by
higher margins. On the other hand, the cost-cutting measures introduced in
the hardware area are not expected to take full effect until 2024. The
expansion of the digital business and thus of recurring sales will also
make the company less dependent on external fluctuations in demand. Vectron
has not yet felt any negative effects from the VAT increase for the
catering industry. On the contrary, digital services are likely to be in
greater demand against the backdrop of staff shortages in the sector.
 
The acquisition of acardo should also make a significant contribution to
sales and earnings in the current 2024 financial year. The couponing
specialist announced the expansion of its couponing network by a further
3,500 stores at the beginning of the year, making it the largest check-out
couponing network in Germany. Against this backdrop, Vectron's guidance
should remain valid and we are maintaining our estimates for the financial
years 2024 and 2025.
 
As part of the DCF valuation model, we have determined a target price of EUR
10.00 (previously: EUR 10.10). The marginal reduction in the target price is
due to the increase in the risk-free interest rate and thus the weighted
cost of capital. On the other hand, we have raised the perpetual growth
rate by 0.5% due to inflation, which has had the effect of increasing the
price target. We continue to assign the BUY rating.
 

You can download the research here:
http://www.more-ir.de/d/28977.pdf

Contact for questions
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
++++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,6a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
https://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date (time) completion: 26.02.24 (10:15 am)
Date (time) first transmission: 26.02.24 (11:30 am)

-------------------transmitted by EQS Group AG.-------------------


The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.

@ dpa.de

Weitere Meldungen

Original-Research: ABO Wind AG (von First Berlin Equity Research GmbH): Buy Original-Research: ABO Wind AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu ABO Wind AG Unternehmen: ABO Wind AG ISIN: DE0005760029 Anlass der Studie: Update Empfehlung: Buy seit: 17.06.2024 Kursziel: 110,00 Euro Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: - Analyst: Dr. (Boerse, 17.06.2024 - 15:11) weiterlesen...

Original-Research: Mountain Alliance AG (von Montega AG): Kaufen Original-Research: Mountain Alliance AG - von Montega AG Einstufung von Montega AG zu Mountain Alliance AG Unternehmen: Mountain Alliance AG ISIN: DE000A12UK08 Anlass der Studie: Update Empfehlung: Kaufen seit: 17.06.2024 Kursziel: 6,00 EUR Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Marcus Silbe (CEFA) Exit-Reife bei der Fokusbeteiligung Lingoda ist gegeben Im Mai hat die Mountain Alliance AG den Geschäftsbericht für 2023 vorgelegt, mit dem die Umstellung auf das HGB-Reporting erfolgte. (Boerse, 17.06.2024 - 11:46) weiterlesen...

Original-Research: sdm SE (von Sphene Capital GmbH): Buy Original-Research: sdm SE - von Sphene Capital GmbH Einstufung von Sphene Capital GmbH zu sdm SE Unternehmen: sdm SE ISIN: DE000A3CM708 Anlass der Studie: Update Report Empfehlung: Buy seit: 17.06.2024 Kursziel: EUR 5,20 (unverändert) Kursziel auf Sicht von: 36 Monate Letzte Ratingänderung: - Analyst: Peter Thilo Hasler, CEFA Akquisition eines Großauftrags Nach der Veröffentlichung von Eckdaten zum ersten Quartal 2024 und der Bekanntgabe des Unternehmens, dass ein neuer Großauftrag akquiriert wurde, ermitteln wir aus unserem dreiphasigen DCF-Entity-Modell (Base-Case-Szenario) ein unverändertes Kursziel von EUR 5,20 je Aktie. (Boerse, 17.06.2024 - 10:32) weiterlesen...

Original-Research: Francotyp-Postalia Holding AG (von GSC Research GmbH): Kaufen Original-Research: Francotyp-Postalia Holding AG - von GSC Research GmbH Einstufung von GSC Research GmbH zu Francotyp-Postalia Holding AG Unternehmen: Francotyp-Postalia Holding AG ISIN: DE000FPH9000 Anlass der Studie: Zahlen erstes Quartal 2024 Empfehlung: Kaufen seit: 17.06.2024 Kursziel: 6,10 Euro Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: 02.12.2019, vormals Halten Analyst: Jens Nielsen Erstes Quartal 2024 im Rahmen der Unternehmenserwartungen Die Zahlen der Francotyp-Postalia Holding AG (FP) zum ersten Quartal des laufenden Geschäftsjahres 2024 fielen operativ verhalten, aber im Rahmen der Unternehmenserwartungen aus. (Boerse, 17.06.2024 - 08:01) weiterlesen...

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Reason for the research: Update Recommendation: Buy from: 14.06.2024 Target price: USD8.50 Target price on sight of: 12 months Last rating change: - Analyst: Christian Orquera First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (Boerse, 14.06.2024 - 14:52) weiterlesen...

Original-Research: The Platform Group AG (von Montega AG): Kaufen Original-Research: The Platform Group AG - von Montega AG Einstufung von Montega AG zu The Platform Group AG Unternehmen: The Platform Group AG ISIN: DE000A2QEFA1 Anlass der Studie: Update Empfehlung: Kaufen seit: 14.06.2024 Kursziel: 13,00 EUR (zuvor: 10,00 EUR) Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst: Ingo Schmidt Anhebung der Prognose und zunehmende Transparenz nach dem Capital Markets Day eröffnen zusätzliches Kurspotential Nachdem THE PLATFORM GROUP (TPG) bereits Ende Mai die Prognosen für das laufende Geschäftsjahr erhöht hatte, nutzte das Unternehmen den Capital Markets Day (11.06.), um die Equity Story einem breiten Publikum zu präsentieren und das Verständnis für das Geschäftsmodell deutlich zu erhöhen. (Boerse, 14.06.2024 - 11:01) weiterlesen...